Table 6.
No | Study | NOP | mST | p Value | Rank | LMG | p Value | mNC | p Value | ETR (95% CI) | p Value | Rank |
1 | Brandes153 | 33 | 9.95 (7.73–12.17) | 0.070 | 1 | 5.18 (2.79–7.56) | 0.104 | 4.60 (3.87–5.33) | <0.001 | 1.13 (0.72 to 1.80) | 0.273 | 2 |
2 | Strik155 | 18 | 8.35 (7.67–9.03) | 0.416 | 2 | 3.58 (1.98–5.17) | 0.506 | 7.30 (6.05–8.55) | <0.001 | 0.49 (0.31 to 0.70) | 0.001 | 6 |
3 | Abacioglu156 | 16 | 6.98 (6.23–7.73) | 0.345 | 6 | 2.20 (1.05–3.35) | 0.486 | 3.33 (2.43–4.22) | 0.004 | 0.66 (0.38 to 1.05) | 0.022 | 3 |
4 | Berrocal157 | 47 | 5.60 (4.16–7.04) | 0.031 | 7 | 0.83 (−0.86–2.51) | 0.073 | 4.55 (3.94–5.16) | <0.001 | 0.18 (−0.05 to 0.44) | <0.001 | 7 |
5 | WA (1–4) | 114 | 7.27 (6.30–8.24) | 0.638 | 4 | 2.50 (1.20–3.80) | 0.718 | 4.20 (3.82–4.57) | <0.001 | 0.59 (0.39 to 0.85) | 0.006 | 4 |
6 | WA (2–4)* | 81 | 7.16 (6.25–8.08) | 0.531 | 5 | 2.39 (1.13–3.65) | 0.633 | 4.13 (3.68–4.57) | <0.001 | 0.58 (0.37 to 0.83) | 0.005 | 5 |
7 | Sahinbas23 | 54 | 7.63 (6.52–8.74) | 1.000 | 3 | 2.85 (1.44–4.26) | 1.000 | 1.56 (1.31–1.81) | 1.000 | 1.83 (1.04 to 4.20) | 1.000 | 1 |
*Main comparator.
LMG, life months gained; NOP, number of patients; WA, weighted average; mNC, mean number of cycles treated; mST, mean survival time since relapse.